Drug Profile

Research programe: chronic kidney disease therapeutics - Arch Biopartners

Alternative Names: CKD platform - Arch Biopartners

Latest Information Update: 12 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lipdro Therapeutics
Developer Arch Biopartners
Class Anti-inflammatories; Urologics
Mechanism of Action Interleukin 32 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Inflammation; Renal failure

Most Recent Events

09 Feb 2026 Preclinical trials in Inflammation in Canada (unspecified route) before February 2026
09 Feb 2026 Preclinical trials in Renal failure in Canada (unspecified route) before February 2026
09 Feb 2026 Arch Biopartners announces intention to submit IND application to US FDA for Renal failure in June 2027

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com